Atara Biotherapeutics is a leading off-the-shelf allogeneic T cell immunotherapy company dedicated to developing new therapies for patients with cancer, and viral diseases. Atara's technology platform makes full use of research collaborations with leading academic institutions, combined with the company's scientific, clinical, regulatory and manufacturing expertise. Atara's product line includes tab-cel® (tabelecleucel), which is in the third phase of development for patients with Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV + PTLD), and for other blood related to EBV Development of systemic malignancies. T cell immunotherapy against EBV antigens is considered very important for the potential treatment of multiple sclerosis; and the next generation of CAR T immunotherapy. The company was founded in 2012 and is located in South San Francisco and Southern California. Their hub in Southern California is based in a state-of-the-art manufacturing facility in Thousand Oaks, California. Atara Biotherapeutics offers numerous employee benefits. This includes group life insurance, short-term disability insurance for accidents or illnesses, long-term disability insurance, fixed-contribution pension plans, flexible spending accounts and health savings account options, among others.
